Etoposide (VP 16-213) induced hepatitis. Report of three cases following standard-dose treatments

Tran, Anthony; Housset, Chantal; Boboc, B.; Tourani, Jean-Marc; Carnot, Françoise; Berthelot, Pièrre

doi:10.1016/0168-8278(91)90905-q

Cited by 37 publications

(11 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Etoposide (VP 16-213), a topoisomerase II inhibitor, is excreted primarily in the bile but is not usually considered hepatotoxic at standard doses [99]. A recent report, however, identified three patients who experienced severe hepatocellular injury at standard doses [100]. At high doses, etoposide has induced hyperbilirubinemia, elevated aminotransferases, and elevated alkaline phosphatase activity approximately three weeks after administration [101,102].…”

Section: Topoisomerase Inhibitorsmentioning

confidence: 99%

Hepatotoxicity of Chemotherapy

Floyd

Mirza

Sachs

et al. 2006

Seminars in Oncology

243

238

View full text Add to dashboard Cite

Section: Topoisomerase Inhibitorsmentioning

confidence: 99%

Hepatotoxicity of Chemotherapy

Floyd

Mirza

Sachs

et al. 2006

Seminars in Oncology

243

238

View full text Add to dashboard Cite

“…A recent report, however, identified three patients who experienced severe hepatocellular injury at standard doses [100]. At high doses, etoposide has induced hyperbilirubinemia, elevated aminotransferases, and elevated alkaline phosphatase activity approximately three weeks after administration [101,102].…”

Section: Topoisomerase Inhibitorsmentioning

confidence: 99%

Hepatotoxicity of Chemotherapy

2001

View full text Add to dashboard Cite

After assessment of tumor histology, the next important factor to consider in the selection of a chemotherapy regime is organ function. Patients who are to receive chemotherapy require careful assessment of liver function prior to treatment to determine which drugs may not be appropriate, and which drug doses should be modified. Following therapy abnormalities of liver function tests may be due to the therapy rather than to progressive disease, and this distinction is of critical importance. Furthermore, not all abnormalities in liver function are due to the tumor or its treatment, and other processes, such as hepatitis, must be kept in mind. This article reviews the hepatic toxicity of chemotherapeutic agents, and suggests dose modifications based upon liver function abnormalities. Emphasis is placed on agents known to be hepatotoxic, and those agents with hepatic metabolism.

show abstract

“…In this case, etoposide is unlikely to have played a causative role in cholestasis. Bile duct damage and cholestasis were present before etoposide was started and etoposide has been associated with hepatocellular necrosis rather than cholestasis or bile duct lesions [7].…”

Section: Discussionmentioning

confidence: 99%